ArticleJAAD case reports2024
Erosive pustular dermatosis-like eruption of the scalp secondary to amivantamab: A case series.
Article in JAAD case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- Innovative therapeutic approach to a rare severe amivantamab-related scalp toxicity: A case report.JAAD case reports · 2026Article
- Aphthous-like ulcerations associated with epidermal growth factor receptor inhibitor targeted therapies: A case series.JAAD case reports · 2026Article
- Scalp and genital ulcerations as cutaneous toxicities of amivantamab and lazertinib combination therapy.JAAD case reports · 2026Article
- Dermatologic adverse events associated with amivantamab: A multicentre study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody-drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Prolonged complete metabolic response to chemotherapy combined with amivantamab with high grade cutaneous toxicity after osimertinib resistance in an uncommonTranslational lung cancer research · 2026Article
- Prevention and Management of Dermatologic Adverse Events in Patients Treated with Amivantamab Plus Lazertinib.Current oncology (Toronto, Ont.) · 2026Article
- Papulopustular eruptions associated with EGFR-pathway-related targeted therapies: clinical spectrum, evidence boundaries, folliculocentric inflammation, and management considerations.Frontiers in oncology · 2026Review
- Erosive pustular dermatosis-like scalp reaction following cranial radiotherapy in a patient with EGFR-mutant NSCLC treated with amivantamab.Oncoscience · 2026Article
- Amivantamab, a bispecific epidermal growth factor receptor and mesenchymal-epithelial transition factor inhibitor, associated with ulcerative intertrigo.JAAD case reports · 2025Article
- Erosive Pustular Dermatosis and Amivantamab for Lung Cancer: A Case Report.Case reports in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.